National Guideline Clearinghouse | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

full-text from ► Clinical Pharmacogenetics Implementation Consortium

National Guideline Clearinghouse | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of <em>G6PD</em> deficiency genotype.



Clinical Pharmacogenetics Implementation Consortium

Guideline Title

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context ofG6PD deficiency genotype.

Bibliographic Source(s)

Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014 Aug;96(2):169-74. [38 references] PubMed

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.

-.-.-



Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelin... - PubMed - NCBI

PMC full text:

Clin Pharmacol Ther. Author manuscript; available in PMC 2014 Aug 1. Published in final edited form as: Clin Pharmacol Ther. 2014 Aug; 96(2): 169–174. Published online 2014 May 2. doi:  10.1038/clpt.2014.97 Copyright/License ►Request permission to reuse

<< PrevFigure 1Next >>

Figure 1

Workflow for interpreting G6PD genotype and for assessing the need for enzyme activity test. *It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified (14).

Clin Pharmacol Ther. 2014 Aug;96(2):169-74. doi: 10.1038/clpt.2014.97. Epub 2014 May 2.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

Relling MV1, McDonagh EM2, Chang T3, Caudle KE1, McLeod HL4, Haidar CE1, Klein T2, Luzzatto L5.

Author information

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia (AHA) induced by a number of drugs. We provide guidance as to which G6PD genotypes are associated with G6PD deficiency in males and females. Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia. Unless preemptive genotyping has established a positive diagnosis of G6PD deficiency, quantitative enzyme assay remains the mainstay of screening prior to rasburicase use. The purpose of this article is to help interpret the results of clinical G6PD genotype tests so that they can guide the use of rasburicase. Detailed guidelines on other aspects of the use of rasburicase, including analyses of cost-effectiveness, are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on https://www.pharmgkb.org/page/cpic to reflect new developments in the field.

PMID:

 

24787449

 

[PubMed - indexed for MEDLINE] 

PMCID:

 

PMC4111801

 

Free PMC Article